Skip to content
Open access

Epigenetic Reactivation of Lineage Differentiation to Target Leukemia

Jul 2026 · bioRxiv · 0 citations · 100 references
Medicine Biology

TL;DR

A selective small-molecule TRIM28 inhibitor is developed that binds the TRIM28 PHD-bromodomain, phenocopies TRIM28 loss across biochemical and cellular assays, exhibits low micromolar anti-leukemia activity, induces neutrophil differentiation, and synergizes with Menin inhibition.

Read PDF

Similar papers

Review Open access 2026

Transcriptional Control as a Therapeutic Strategy in Acute Myeloid Leukemia

: Acute myeloid leukemia (AML) is driven by dysregulated transcription factors (TFs) that disrupt hematopoietic differentiation, promote leukemic self-renewal, and confer therapy resistance. Key TFs including C/EBP α , PU.1, RUNX1, GATA2, EVI1, PML-RAR α fusion protein, p53, c-Myc and ERG are altered through mutations,...

Annisa Nurul Ilmi, Rudy Agung Nugroho, Sendy Junedi et al. · 0 citations
Sep 2026

IRF1-driven chromatin and transcriptional regulation determines the anti-tumor responses to all-trans retinoic acid across cancer types.

It is indicated that IRF1-dependent chromatin and transcriptional regulation contribute to the diverse anti-tumor effects of ATRA and provide a framework for biomarker-guided evaluation of ATRA in cancer therapies.

W. Jin, Peng Jin, Yun Tan et al. · 1 citation
Aug 2026

SETD5 regulates leukemic initiation and infiltration in T-cell acute lymphoblastic leukemia.

It is demonstrated that SETD5 contributes to T-ALL progression by regulating transcriptional programs that contribute to leukemic cell migration and infiltration, suggesting that SETD5-associated transcriptional programs warrant further investigation as potential vulnerabilities in T-ALL.

Ming-Yue Hao, Yu-Jie Bian, Mengke Li et al. · 0 citations
Review Sep 2026

Targeting the Epigenetic–Immune Axis in Acute Myeloid Leukemia: Current Advances and Future Directions

Ep epigenetic dysregulation is highlighted as both a fundamental driver of leukemogenesis and a clinically actionable therapeutic interface that may enable more rational treatment sequencing and personalized AML management.

Devangi Ghosh, Mohd Ayoub, Surajit Karmakar et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.